Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.

NCT04877457 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Slow enrollment

Conditions

Radiologically Isolated Syndrome
Multiple Sclerosis

Interventions

DRUG: Ocrelizumab
OTHER: Placebo

Sponsor

Yale University

Collaborators

[object Object]